CN110368500A - A kind of amphipathic copolymer prodrug, preparation method and the nano particle for containing its salts - Google Patents
A kind of amphipathic copolymer prodrug, preparation method and the nano particle for containing its salts Download PDFInfo
- Publication number
- CN110368500A CN110368500A CN201910630574.XA CN201910630574A CN110368500A CN 110368500 A CN110368500 A CN 110368500A CN 201910630574 A CN201910630574 A CN 201910630574A CN 110368500 A CN110368500 A CN 110368500A
- Authority
- CN
- China
- Prior art keywords
- ethyl
- poly
- hydroxycamptothecin
- salts
- amphipathic copolymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/10—Esters
- C08F220/26—Esters containing oxygen in addition to the carboxy oxygen
- C08F220/28—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/10—Esters
- C08F220/34—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate
- C08F220/36—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate containing oxygen in addition to the carboxy oxygen, e.g. 2-N-morpholinoethyl (meth)acrylate or 2-isocyanatoethyl (meth)acrylate
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/10—Esters
- C08F220/26—Esters containing oxygen in addition to the carboxy oxygen
- C08F220/28—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety
- C08F220/282—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety and containing two or more oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of amphipathic copolymer prodrug containing 7-Ethyl-10-hydroxycamptothecin, including one section of polyethylene glycol as hydrophilic section and poly- (7-Ethyl-10-hydroxycamptothecin) and poly- cholesterol as hydrophobic section；Wherein poly- (7-Ethyl-10-hydroxycamptothecin) forms degradable chemical bond by hydroxyl with poly- cholesterol and is connected, and poly- (7-Ethyl-10-hydroxycamptothecin) and poly- cholesterol are connected by forming degradable chemical bond with poly glycol monomethyl ether skeleton.The invention also discloses the preparation method of above-mentioned precursor and contain the nano particle of its salts.The present invention contains compound its salts while being self-assembly of nano particle in water, improve the solubility of 7-Ethyl-10-hydroxycamptothecin and its salts in water, obtained nano particle can pass through the activity of inhibition sternzellen, extracellular matrix is reduced, to increase the infiltration and therapeutic effect of chemotherapeutics.
Description
Technical field
The present invention relates to a kind of prodrug and its preparation fields, and in particular to a kind of 7-Ethyl-10-hydroxycamptothecin two
Parent's property copolymer prodrug and its preparation method and application.
Background technique
7-Ethyl-10-hydroxycamptothecin (abbreviation SN-38), is one of important derivatives of camptothecine, and molecular formula is
C22H20N2O5, molecular weight 392.31, CAS.NO:86639-52-3, structural formula is as follows:
SN-38 is one of camptothecin anticancer drug.Clinically, in camptothecine, use is had been approved by
Have an Irinotecan and topotecan, these two types of drugs are to be repaired respectively by carrying out functional group to SN-38,10-hydroxycamptothecine
What the mode of decorations obtained, improve the dissolubility of camptothecine in water.SN-38 is that Irinotecan is metabolized obtains in vivo
Activated product, its pharmacological property can achieve 1000 times of Irinotecan in some cell strains, still, since its is very poor
Water solubility is restricted in vivo so that it is directly applied to.
Cancer be endanger the important diseases of human health, and the distinguishing feature of the high cancer of many lethalities be exactly have it is rich
Rich and fine and close collagen stroma (Sermour, A.B.；Hruban,R.H.；Redston,M.et al.Allelotype of
Pancreatic Adenocarcinoma [J] .Cancer Res, 1994,54 (10): 2761-4.), it grows present in colloid
The factor, osteopontin, periostin, acid serine stretch protein and cysteine all can be between the phases tumour cell and extracellular base
Important regulating and controlling effect is played in interaction, not only promotes the transfer of tumour cell and enhances the drug resistance of tumour cell, and
Thick and heavy collagen stroma hinders the infiltration of drug.
In numerous cells in tumor microenvironment, sternzellen is wherein to study cell the most deep, micro- to tumour
The colloid secreted in environment plays decisive role (Hanahan, D.；Coussens,L.M.Accessories to the
crime functions of cells recruited to the tumor microenvironment[J].Cancer
cell,2012,21(3):309-22.).And there are two states, tranquillization state and activated states for sternzellen: in the pancreas of human normal
In glandular tissue, pancreatic stellate cells usually with the presence of tranquillization state, probably account for the 4%-7% of human pancreas' normal parenchyma cell；Swash
The dense collagenous stroma that the sternzellen of state living generates reduces penetrating power (Netti, the P.A. of drug；Berk,D.A.；
Swartz,M.A.et al.Role of extracellular matrix assembly in interstitial
transport in solid tumors[J].Cancer Res,2000,60(9):2497-503.)。
Its salts is a kind of important vitamin D derivative, can significantly reverse the state of activation of sternzellen, but its
Strong toxicity, side effect is big, and water-soluble extremely low, compound crystallinity is strong, it is difficult to contain, and the half-life period pole of its salts itself
It is short, only 4 minutes, be very easy to inactivation in human body, be metabolized into the very poor two kinds of metabolites of activity (Kragballe,
K.Calcipotriol-a New Drug for Topical Psoriasis Treatment[J]
.PharmacolToxicol,1995,77(4):241-6.).Some researches show that its salts and chemotherapy drugs in combination use to increase
Add chemotherapeutical medicine curative effect (Sherman, M.H.；Yu,R.T.；Engle,D.D.et al.Vitamin D Receptor-
Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances
Pancreatic Cancer Therapy[J].Cell,2014,159(1):80-93.)。
Application No. is the specification of CN200410048016 disclose a kind of branch polyethylene glycol-amino acid oligopeptides and its
Drug conjugates, the polymer include multiple active groups, derive linear polyethylene glycol by these groups, ultimately form more
Pitch the polyethylene glycol of branch.
A kind of drug that SN-38 is linked with short chain PEG is disclosed in Publication No. CN102060991A, which has non-
Often high cytotoxicity.Publication No. CN103251596A discloses a kind of amphipathic polymerization of 7-Ethyl-10-hydroxycamptothecin
Object prodrug, including one section of polyethylene glycol and one section poly- (7-Ethyl-10-hydroxycamptothecin)；Poly- (7- ethyl-the 10-
Hydroxycamptothecin) it is to pass through degradable chemical bond and poly- by 10 in 7-Ethyl-10-hydroxycamptothecin or/and 20 hydroxyls
Polymer backbone is connected, by introducing the polyethylene glycol of different length, so that the prodrug is self-assembly of nanometer in water
Grain, improves the solubility of 7-Ethyl-10-hydroxycamptothecin in water.
Summary of the invention
The present invention provides a kind of amphipathic copolymer prodrug of 7-Ethyl-10-hydroxycamptothecin, the prodrug is logical
Introducing cholesterol is crossed, so that the prodrug easily dissolves in water, to efficiently contain its salts, is made it have very high swollen
Tumor toxicity and normal tissue toxicity is lower.
The amphipathic copolymer prodrug of the 7-Ethyl-10-hydroxycamptothecin, including one section of poly glycol monomethyl ether
As the hydrophobic section that hydrophilic section and poly- (7-Ethyl-10-hydroxycamptothecin) and poly- cholesterol form, poly- (the 7- ethyl-
10-hydroxycamptothecine) and poly- cholesterol be connected by forming degradable chemical bond with poly glycol monomethyl ether skeleton.
The number of poly glycol monomethyl ether is equal in the amphipathic copolymer prodrug of the 7-Ethyl-10-hydroxycamptothecin
Molecular weight is 550-20000, and the number-average molecular weight of poly- (7-Ethyl-10-hydroxycamptothecin) is 600-60000, the poly- gallbladder
The number-average molecular weight of sterol is 600-60000.
The degradable chemical bond is selected from urea bond, ester bond, carbonic acid ester bond, urethane bond, phosphoric acid ester bond etc. in vivo
The one or two of degradable chemical key.
When the degradable chemical bond is ester bond, described-the amphipathic copolymer drug of ethyl-10-hydroxycamptothecin
Precursor is under the action of condensing agent by 7- ethyl -10- hydroxy-camptothecin and using one or more carboxyls as the polyethylene glycol of end group
Reaction obtains；The condensing agent is selected from N, N '-dicyclohexylcarbodiimide (DCC), 1- (3- dimethylamino) -3- ethyl carbon two
Imines (EDC), N, one of N '-diisopropylcarbodiimide (DIPC) etc..
Preferably, amphipathic copolymer prodrug (the abbreviation PEG-PSN- of the 7-Ethyl-10-hydroxycamptothecin
38-PCHL), it is the compound of the structure as shown in following formula I:
In Formulas I, the number-average molecular weight of the poly glycol monomethyl ether is 550-20000 (x=10-500), poly- (7- ethyl-
10-hydroxycamptothecine) number-average molecular weight be 600-60000 (y=1-100), the number-average molecular weight of the poly- cholesterol is
600-60000 (z=1-100).
The amphipathic copolymer prodrug of the 7-Ethyl-10-hydroxycamptothecin, can be self-assembly of nano particle
(or micella or vesica).Due to the addition of poly- cholesterol section, its salts can be efficiently contained, thus can be in an aqueous solvent
It is self-assembled into the nano particle for containing its salts, preparation method includes dialysis, membrane process, solvent evaporated method etc..
The present invention also provides a kind of preparation method of the amphipathic copolymer prodrug of 7-Ethyl-10-hydroxycamptothecin,
Yield is high, and method is simple, is suitble to industrialized production.
The preparation method of the amphipathic copolymer prodrug of the 7-Ethyl-10-hydroxycamptothecin includes:
(1) poly glycol monomethyl ether and micromolecule chain transfer agent PETTC are dissolved into organic solvent, dicyclohexyl is added
Carbodiimide and 4-dimethylaminopyridine catalysis reaction, washing, drying are precipitated with anhydrous ether, obtain structure shown in formula a
Poly glycol monomethyl ether compound；
WhereinXFor 10-500
(2) 7-Ethyl-10-hydroxycamptothecin and mono succinate [2- [(2- methyl-acryloyl) oxygen] ethyl] ester are added
Enter into organic solvent, under the effect of 1- (3- dimethylamino-propyl) -3- ethyl carbodiimide, more than room temperature reaction for 24 hours, through washing
It washs, dry, being concentrated, crossing column, obtaining the 7-Ethyl-10-hydroxycamptothecin derivative (abbreviation MMESSN-38) of structure shown in formula b；
(3) cholesteryl chloroformate and hydroxyethyl methacrylate are dissolved in organic solvent, are made in anhydrous pyridine
Under catalytic action, overnight, column is crossed in washed, dry, concentration for reaction, obtains the cholesterol derivative of structure shown in formula c (referred to as
MACHL)；
(4) by the poly glycol monomethyl ether compound of structure shown in formula a, the poly- (7- ethyl -10- hydroxyl of structure shown in formula b
Camptothecine) structure shown in compound and formula c the dissolution of poly- cholesterol cpds in organic solvent, in azodiisobutyronitrile
Under catalytic action, under the conditions of anhydrous and oxygen-free more than heating reaction for 24 hours, dialysis removes small molecule, obtains 7- ethyl -10- shown in formula I
The amphipathic copolymer prodrug of hydroxycamptothecin.
The organic solvent include methylene chloride, methyl phenyl ethers anisole, chloroform, tetrahydrofuran, pyridine, dimethyl sulfoxide,
N, one of reaction dissolvents such as N '-dimethyl formamide.
The present invention also provides the amphipathic copolymer prodrug assemblings of 7-Ethyl-10-hydroxycamptothecin to contain calcium pool three
The preparation method of the nano particle of alcohol, including dialysis, membrane process and solvent evaporated method.
Preferably, by taking dialysis as an example, the amphipathic copolymer prodrug packet of the 7-Ethyl-10-hydroxycamptothecin
The preparation method for carrying the nano particle of its salts includes: before weighing the amphipathic copolymer drug of 7-Ethyl-10-hydroxycamptothecin
Body powder, is dissolved in organic solvent, and its salts is added, is sufficiently mixed, deionized water is slowly added dropwise to solution, sufficiently stirs
It mixes, after being added dropwise to complete, is dialysed using semi-permeable membrane and remove organic solvent, after centrifugation removes free small molecule compound, pass through room temperature
Vacuum distillation, it is molten to obtain the nano particle that the amphipathic copolymer prodrug of 7-Ethyl-10-hydroxycamptothecin contains its salts
Liquid.
The organic solvent used in involved nano particle production method includes tetrahydrofuran, dimethyl sulfoxide, N, N '-two
One of the solvent that methylformamide etc. is mixed with water.
The amphipathic copolymer prodrug of the 7-Ethyl-10-hydroxycamptothecin contains the nano particle of its salts
Size range be 10nm-300nm, the size of nano particle and the amount for containing its salts can be by controlling poly- (7- second
Base -10-hydroxycamptothecine) and the molecular weight of poly- cholesterol reach.The size of control nano particle and contained its salts
Amount pharmacokinetics numerical value in drug body can be made to be controlled so that same preparation for treating various cancers, patient
Propertyization treatment is possibly realized.
The invention has the following advantages:
Due to being bonded 7- ethyl -10- hydroxy-camptothecin in the amphipathic copolymer prodrug of 7-Ethyl-10-hydroxycamptothecin
The chemical bond of alkali can be efficiently broken at tumour, therefore the polymer prodrug is with very high tumor toxicity and to normal group
It is lower to knit toxicity.
Since 7-Ethyl-10-hydroxycamptothecin tool hydrophobicity is very strong, by introducing poly glycol monomethyl ether, so that the medicine
Object precursor is self-assembly of nano particle in water, greatly improves the dissolution of 7-Ethyl-10-hydroxycamptothecin in water
Degree, makes it possible its vivo applications.The prodrug nano-micelle has high drugloading rate simultaneously, it is possible to reduce drug
Usage amount, to reduce side effect of the drug in health tissues.
Since its salts can efficiently inhibit the activity of sternzellen, reduce sternzellen to the proliferation of tumour, drug resistance and
Transferance.By the way that cholesterol must be introduced 7-Ethyl-10-hydroxycamptothecin polymer prodrug is innovative, efficiently contain
Its salts forms nano particle, significantly reduces the distribution of its salts in the normal tissue, and makes the reduction of its toxic side effect.
Detailed description of the invention
Fig. 1 is the hydrogen nuclear magnetic resonance spectrogram of poly glycol monomethyl ether compound prepared by embodiment 1；
Fig. 2 is the hydrogen nuclear magnetic resonance spectrogram of MMESSN-38 prepared by embodiment 1；
Fig. 3 is the hydrogen nuclear magnetic resonance spectrogram of MACHL prepared by embodiment 1；
Fig. 4 is the hydrogen nuclear magnetic resonance spectrogram of PEG-PSN-38-PCHL prepared by embodiment 1；
Fig. 5 is the gel permeation chromatography phenogram of PEG-PSN-38-PCHL prepared by embodiment 1；
Fig. 6 is the critical micelle concentration CMC measurement chart of PEG-PSN-38-PCHL prepared by embodiment 1；
Fig. 7 is that the dynamic optical for the nano particle that PEG-PSN-38-PCHL prepared by embodiment 1 contains its salts formation dissipates
Penetrate figure；
Fig. 8 A is the transmission electricity for the nano particle that PEG-PSN-38-PCHL prepared by embodiment 1 contains its salts formation
Mirror figure, Fig. 8 B are the enlarged drawing of Fig. 8 A；
Fig. 9 is that PEG-PSN-38-PCHL prepared by embodiment 1 contains 7- ethyl-in the nano particle of its salts formation
The in-vitro release rate figure of 10-hydroxycamptothecine and its salts.
Specific embodiment
Below in conjunction with specific the drawings and specific embodiments, invention is further described in detail, it should be noted that, below
It does not limit the scope of the invention.
Embodiment 1
The amphipathic copolymer prodrug of 7-Ethyl-10-hydroxycamptothecin shown in Formulas I is synthesized, wherein polyethylene glycol number is equal
Molecular weight is 5000, and 7-Ethyl-10-hydroxycamptothecin residue number is 12 in poly- (7-Ethyl-10-hydroxycamptothecin) block, point
Son amount is 7200, and cholesterol residue number is 4 in poly- cholesterol block, molecular weight 2100.
One, the synthesis of poly glycol monomethyl ether compound
Taking 2.5g molecular weight is 5000 poly glycol monomethyl ether (0.5mmol), is dissolved in 50mL toluene, reflux removes water to
The toluene steamed becomes to clarify, and 50mL methylene chloride, ice bath cooling is added under nitrogen protection, and be added under condition of ice bath
Small molecule PETTC and the 20mL 4- containing 12mg containing 4 equivalents is slowly added dropwise in 300mg dicyclohexylcarbodiimide (1mmol)
The methylene chloride of dimethylamino naphthyridine (0.1mmol).Overnight, 1N aqueous hydrochloric acid solution washs 3 times, saturated salt solution for reaction at room temperature
Washing 3 times, anhydrous sodium sulfate is dry, concentrated by rotary evaporation, and places and recrystallize in -20 DEG C of ether, collects precipitating, cold anhydrous ether
Three times, normal-temperature vacuum oven drying obtains product (2.1g, yield 74%) for washing.Obtain poly glycol monomethyl ether compound nuclear-magnetism
Map is as shown in Figure 1.
Examine the nuclear-magnetism figure swarming of poly glycol monomethyl ether compound as follows:1H NMR of mPEG5K-PETTC in
CDCl3.(400MHz,CDCl3, 298K): δ (ppm)=1.90 (s, 3H ,-CH3),2.37-2.61(m,4H,-CH2),3.0(t,
2H,-CH2),3.38(s,3H,-CH3),3.43-3.83(m,456H),7.23-7.34(m,5H).
Two, the synthesis of MMESSN-38
It weighs 7-Ethyl-10-hydroxycamptothecin 2g (5mmol), mono succinate [2- [(the 2- methyl-of 2.4g (10mmol)
Acryloyl group) oxygen] ethyl] ester, it is dissolved in 150mL methylene chloride, it is rear that 18mL anhydrous pyridine is added, it is stirred under ice bath environment, it will
1.9g (10mmol) 1- (3- dimethylamino-propyl) -3- ethyl carbodiimide (EDC) is dissolved in 25mL dichloromethane solution and passes through perseverance
Pressure dropping funel slowly drips, and is stirred overnight at room temperature after being added dropwise to complete.Reaction to solution is clarified, and filtrate, concentration 1N are collected in filtering
Dilute hydrochloric acid solution wash 3 times, extraction recrystallizes in concentrated by rotary evaporation, with -20 DEG C of ice ether, obtains the thick production of MMESSN-38
Object, and using methylene chloride/anhydrous methanol eluent of volume ratio 95:5, by column Chromatographic purification on 200 mesh silicagel columns, obtain
It is as shown in Figure 2 to MMESSN-38 1.4g (yield 46%) nuclear magnetic spectrum.
Examine the nuclear-magnetism figure swarming of MMESSN-38 as follows:1H NMR of MMESSN-38in CDCl3.(400MHz,
CDCl3, 298K) and δ=8.32 (d, J=9.2Hz, 1H), 7.94-7.70 (m, 2H), 7.58 (dd, J=9.2,2.3Hz, 1H),
6.13 (s, 1H), 5.74 (d, J=16.4Hz, 1H), 5.62-5.46 (m, 1H), 4.53-4.18 (m, 4H), 3.18 (q, J=
7.6Hz, 2H), 3.00 (t, J=6.6Hz, 2H), 2.85 (t, J=6.6Hz, 2H), 2.10-1.69 (m, 5H), 1.41 (t, J=
7.6Hz, 3H), 1.04 (t, J=7.4Hz, 3H)
Three, the synthesis of MACHL
9.0g cholesteryl chloroformate (20mmol) is taken, is dissolved in 100mL dry methylene chloride, the anhydrous of 22mol is added
Pyridine (1.75g).The 30mL dry methylene chloride for containing 3.9g hydroxyethyl methacrylate (30mol) is added dropwise under condition of ice bath,
It is stirred overnight at room temperature.It is washed 3 times using the dilute hydrochloric acid solution that concentration is 1N, concentrated by rotary evaporation after drying uses 200 mesh silicagel columns
Purifying, eluant, eluent are methylene chloride/n-hexane=3:1, collect filtrate, are spin-dried for being placed on vacuum drying oven and are dried overnight, and obtain gallbladder
Sterol monomer (5.4g, yield 47%) nuclear magnetic spectrum is as shown in Figure 3.
Examine the nuclear-magnetism figure swarming of MACHL as follows:1H NMR of MMESSN-38in CDCl3(400MHz,CDCl3,
298K): δ (ppm)=0.55-2.04 (m, 41H ,-CH3,-CH(CH3)-,-CH-,-CH2-),2.32-2.51(m,2H,-CH2),
4.32(s,4H,-CO-O-CH2-CH2-O-CO-),4.48-4.50(m,1H,-CHO-),5.39-5.40(m,1H,-C(CH2)=
CH-),5.55-5.60(m,1H,CH3- C=CH2),6.10-6.20(m,1H,CH3- C=CH2).
Four, the synthesis of PEG-PSN38-PCHL
The synthesis of block polymer PEG-PSN-38 uses RAFT free radical polymerization, as shown, macromolecular chain is taken to shift
Agent PEG-PETTC 213mg (0.04mmol), SN-38 monomer MMESSN-38 250mg (0.42mmol) cholesterol monomer MACHL
100mg (0.17mmol) and AIBN (3.3mg, 0.02mmol), the DMSO and 1mL that co-dissolve is removed water in 1mL calcium hydride are dry
In dry dioxane, ultrasound sufficiently dissolution.Nitrogen is bubbled 30min, and freeze-thaw method removes water deoxygenation 3-5 times, then seals polymerization bottle
It closes, is placed in polymerization reaction 16h in 70 DEG C of oil bath pan.Polymerization bottle is placed in liquid nitrogen after reaction and is freezed, bottle stopper is opened and exists
It slowly heats up, solution is placed in the semi-permeable membrane bag filter that molecular cut off is 3500Da, with the DMSO of 250mL in ethanol solution
Solution is dialysed 3 times under 40 DEG C of environment, 12 hours every time, is then dialysed 3 times under 40 DEG C of environment with the DMF solution of 250mL, often
Secondary 12 hours.DMF is replaced as water, freezing obtains product (280mg, yield 50%), and the nuclear magnetic spectrum of product is as shown in Figure 4.
Examine the nuclear-magnetism figure swarming of PEG-PSN38-PCHL as follows:1H NMR of PEG-PSN38-PCHL in CDCl3.
(400MHz,CDCl3, 298K) and δ (ppm)=7.02-8.52 (dd, 48H), 6.47 (s, 14H), 5.82-5.73 (d, 48H),
3.78-4.58 (d, 64H), 3.39-3.83 (m, 452H), 2.96 (d, J=28.0Hz, 12H), 2.83-2.63 (m, 12H),
2.63-2.27(m,32H),2.14(s,48H),1.84(s,48H),1.55-0.05(m,50H).
The gel exclusion chromatography figure of acquired product is as shown in figure 5, the retention time of product PEG-PSN38-PCHL is significant
Lower than macromole evocating agent PEG-PETTC.PEG-PSN38-PCHL can be spontaneously assemble into nano particle in water, pass through Nile red
Method measures critical micelle concentration needed for it forms nano particle, as shown in fig. 6, its critical micelle concentration is 46.64 μ g/mL.
Said synthesis route is as follows:
Five, the amphipathic copolymer prodrug assembling of 7-Ethyl-10-hydroxycamptothecin contains the nano particle of its salts
Preparation
It weighs 5mg PEG-PSN-38-PCHL polymer powder to be dissolved in 1mL DMSO, separately takes 10mg its salts molten
Solution is made into its salts stock solution in 1mL DMSO, and the DMSO for taking 75 μ L its salts stock solutions that 1mL polymer is added is molten
In liquid, polishing to 1.5mL DMSO is sufficiently mixed ultrasound 5 minutes, and 5mL deionized water is slowly added dropwise thereto, is sufficiently stirred ten
After five minutes, dialysed three times in 500mL deionized water with acetate fiber pellicle (molecular cut off 3500Da), every time two
Hour.After the completion of dialysis, 3300rpm is centrifuged 5 minutes, and it is suitable for dense that polymer is concentrated to by supernatant by 35 DEG C of vacuum distillations
Degree.The concentration that wherein its salts and 7-Ethyl-10-hydroxycamptothecin are measured by high performance liquid chromatography, calculates its encapsulation rate.
As shown in fig. 7, containing the nano particle diameter after its salts, gained nanometer by dynamic light scattering measurement
Grain partial size is 110 nanometers, the shape characteristic of the nano particle as obtained by transmission electron microscope characterization；It as shown in Figure 8 A, can be with
It was found that the nano particle formed after containing its salts is the more uniform spherical nanoparticles of size.Electron microscope is further put
Greatly, by Fig. 8 B it is found that the spherical nanoparticle partial size is about 100 nanometers, its salts in dialysis measurement nano particle is used
With the rate of release of 7-Ethyl-10-hydroxycamptothecin, i.e., gained nano particle is placed in molecular cut off is 3500 dalton
In semi-permeable membrane bag filter, then bag filter is mixed in the drug concentration measured outside bag filter in buffer solution；As shown in figure 9, calcium
It moors three pure and mild 7-Ethyl-10-hydroxycamptothecin gradually to discharge, its salts rate of release is faster than 7- ethyl -10- hydroxy-camptothecin
Alkali has haved the function that two kinds of drug control sustained releases.
Claims (10)
1. a kind of amphipathic copolymer prodrug characterized by comprising poly glycol monomethyl ether is as hydrophilic section and gathers
(7-Ethyl-10-hydroxycamptothecin) and poly- cholesterol are poly- (7-Ethyl-10-hydroxycamptothecin) and poly- as hydrophobic section
Cholesterol is connected by forming degradable chemical bond with poly glycol monomethyl ether skeleton.
2. amphipathic copolymer prodrug according to claim 1, which is characterized in that the poly glycol monomethyl ether
Number-average molecular weight be 550-20000.
3. amphipathic copolymer prodrug according to claim 1, which is characterized in that the poly- (7- ethyl -10-
Hydroxycamptothecin) number-average molecular weight be 600-60000.
4. amphiphilic polymer prodrug according to claim 1, which is characterized in that the number of the poly- cholesterol is equal
Molecular weight is 600-60000.
5. amphipathic copolymer prodrug according to claim 1, which is characterized in that the amphipathic copolymer medicine
Object precursor is the compound of the structure as shown in following formula I:
Wherein, x 10-500, y 1-100, z 1-100.
6. the preparation method of amphipathic copolymer prodrug according to claim 5, comprising:
(1) poly glycol monomethyl ether and micromolecule chain transfer agent PETTC are dissolved into organic solvent, dicyclohexyl carbon two is added
Imines and 4-dimethylaminopyridine catalysis reaction, washing, drying are precipitated with anhydrous ether, obtain the poly- second of structure shown in formula a
Glycol monomethyl ether compound；
WhereinXFor 10-500；
(2) 7-Ethyl-10-hydroxycamptothecin and mono succinate [2- [(2- methyl-acryloyl) oxygen] ethyl] ester are added to
In organic solvent, under the effect of 1- (3- dimethylamino-propyl) -3- ethyl carbodiimide, room temperature reaction, wash, is dry, being concentrated,
Column is crossed, the 7-Ethyl-10-hydroxycamptothecin derivative of structure shown in formula b is obtained；
(3) cholesteryl chloroformate and hydroxyethyl methacrylate are dissolved in organic solvent, in the catalysis that anhydrous pyridine is made
Under effect, overnight, washing, crosses column at dry, concentration for reaction, obtains the cholesterol derivative of structure shown in formula c；
(4) by the poly glycol monomethyl ether compound of structure shown in formula a, the 7-Ethyl-10-hydroxycamptothecin of structure shown in formula b
The cholesterol derivative dissolution of structure shown in derivative and formula c in organic solvent, in the catalytic action of azodiisobutyronitrile
Under, reaction is heated under the conditions of anhydrous and oxygen-free, dialysis obtains the amphipathic copolymer medicine of 7-Ethyl-10-hydroxycamptothecin shown in formula I
Object precursor.
7. the preparation method of amphipathic copolymer prodrug according to claim 6, which is characterized in that described is organic
Solvent includes methylene chloride, methyl phenyl ethers anisole, chloroform, tetrahydrofuran, pyridine, dimethyl sulfoxide and N, N '-dimethyl formamide
One of.
8. amphipathic copolymer prodrug described in a kind of any claim according to claim 1~5 and its salts assemble
The nano particle for containing its salts formed.
9. the nano particle according to claim 8 for containing its salts, which is characterized in that the ruler of the nano particle
Very little range is 10nm-300nm.
10. the preparation method of the nano particle according to claim 8 for containing its salts, which is characterized in that using saturating
One of analysis method, membrane process, solvent evaporated method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910630574.XA CN110368500B (en) | 2019-07-12 | 2019-07-12 | Amphiphilic copolymer prodrug, preparation method and calcipotriol-entrapped nanoparticles |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910630574.XA CN110368500B (en) | 2019-07-12 | 2019-07-12 | Amphiphilic copolymer prodrug, preparation method and calcipotriol-entrapped nanoparticles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110368500A true CN110368500A (en) | 2019-10-25 |
| CN110368500B CN110368500B (en) | 2020-06-30 |
Family
ID=68252930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910630574.XA Active CN110368500B (en) | 2019-07-12 | 2019-07-12 | Amphiphilic copolymer prodrug, preparation method and calcipotriol-entrapped nanoparticles |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110368500B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113801839A (en) * | 2021-09-17 | 2021-12-17 | 东南大学 | Method for extracting stellate cells of static pancreas of rat |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004017940A2 (en) * | 2002-08-20 | 2004-03-04 | Neopharm, Inc. | Pharmaceutically active lipid based formulation of sn38 |
| CN1875946A (en) * | 2006-07-12 | 2006-12-13 | 张文芳 | Nanoparticle of 10-hydroxycamtothecine and preparation method thereof |
| AU2008227852A1 (en) * | 2007-03-19 | 2008-09-25 | Fresenius Kabi Oncology Ltd. | Proliposomal and liposomal compositions |
| CN104274401A (en) * | 2014-07-25 | 2015-01-14 | 中国医学科学院药用植物研究所 | High drug-loading content nano suspension for camptothecin medicine based on HCPT-PEG (hydroxycamptothecin-polyethylene glycol) and preparation method of high drug-loading content nano suspension |
| CN105315294A (en) * | 2014-06-26 | 2016-02-10 | 王杭祥 | 7-ethyl-10-hydroxycamptothecine drug precursor, preparation method and application thereof |
-
2019
- 2019-07-12 CN CN201910630574.XA patent/CN110368500B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004017940A2 (en) * | 2002-08-20 | 2004-03-04 | Neopharm, Inc. | Pharmaceutically active lipid based formulation of sn38 |
| CN1875946A (en) * | 2006-07-12 | 2006-12-13 | 张文芳 | Nanoparticle of 10-hydroxycamtothecine and preparation method thereof |
| AU2008227852A1 (en) * | 2007-03-19 | 2008-09-25 | Fresenius Kabi Oncology Ltd. | Proliposomal and liposomal compositions |
| CN105315294A (en) * | 2014-06-26 | 2016-02-10 | 王杭祥 | 7-ethyl-10-hydroxycamptothecine drug precursor, preparation method and application thereof |
| CN104274401A (en) * | 2014-07-25 | 2015-01-14 | 中国医学科学院药用植物研究所 | High drug-loading content nano suspension for camptothecin medicine based on HCPT-PEG (hydroxycamptothecin-polyethylene glycol) and preparation method of high drug-loading content nano suspension |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113801839A (en) * | 2021-09-17 | 2021-12-17 | 东南大学 | Method for extracting stellate cells of static pancreas of rat |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110368500B (en) | 2020-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103705940B (en) | The preparation of a kind of natural activity medicine-polysaccharide targeting complex and antineoplastic application thereof | |
| CN102060991B (en) | Amphiphilic prodrug of 7- ethyl-10-hydroxycamptothecin and preparation method thereof | |
| CN103333301B (en) | Amphiphilic pH-responsive 4/6 heteroarm star-shaped copolymer and preparation method thereof | |
| CN102475891A (en) | PH-responsive polyethylene glycol-anticarcinogen conjugate, and synthetic method and application thereof | |
| CN103483582B (en) | Biodegradable polymer vesicles of pH response and preparation method thereof and application | |
| CN111330014B (en) | Acid-responsive cross-linked polymer prodrug and preparation method and application thereof | |
| CN113105614A (en) | Easily degradable responsive core-crosslinkable amphiphilic block polymer, preparation method thereof and application of polymer as drug carrier | |
| CN108066770A (en) | Amphipathic nature polyalcohol prodrug of reduction response release active compound and preparation method thereof | |
| CN105860057B (en) | Biodegradable polymer based on the hydrophilic polyaminoacid of hydrophobic function small molecule and its preparation method and application | |
| CN105968370B (en) | The polyethylene glycol polycaprolactone triblock polymer and its preparation method and application of triple disulfide bond connections | |
| CN105504293B (en) | A kind of preparation and application of fluorescence star block copolymer | |
| CN101234205B (en) | High molecule adriamycin bonding medicine nano capsule with targeting function and preparation thereof | |
| CN110368500A (en) | A kind of amphipathic copolymer prodrug, preparation method and the nano particle for containing its salts | |
| CN104650307B (en) | PH five block linear polymers of sensitivity and micella based on PDEAEMA | |
| CN113101373B (en) | Hollow mesoporous silica drug-loaded particle with light-stimulated active oxygen response and preparation method and application thereof | |
| CN104817688A (en) | Convertible surface charge nano-gel, preparation method thereof and convertible surface charge nano-gel drug-loaded particle | |
| CN113512200B (en) | Molecular brush polymer with poly-L-glutamic acid ester as main chain, and preparation method and application thereof | |
| CN104761732A (en) | Tumor cell targeted nano gel and preparation method thereof as well as tumor cell targeted drug-loaded nano-particles | |
| WO2018102973A1 (en) | Pegylated vitamin e periplocymarin conjugate nanoparticles and preparation method therefor | |
| KR20120126356A (en) | Nanoparticles comprising amphiphilic low molecular weight hyaluronic acid complex and a process for the preparation thereof | |
| CN104415339A (en) | Self-assembled targeted nanometer drug carrier micelles | |
| CN103709410B (en) | Acid-sensitive amphipathic segmented copolymer and self-organization micella, purposes | |
| CN112138001A (en) | Quercetin-low molecular weight heparin-paclitaxel conjugate, preparation method and application | |
| CN105169405A (en) | Preparation method of adriamycin polymer drug | |
| CN103212086B (en) | A kind of high drug load Podophyllum emodi var chinense nano-prodrug and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210507 Address after: 315800 room a812, No.2 Xingye Avenue, Ningbo Free Trade Zone, Ningbo City, Zhejiang Province Patentee after: Ningbo Ningrui Biotechnology Co.,Ltd. Address before: 310013 Yuhang Tang Road, Xihu District, Hangzhou, Zhejiang 866 Patentee before: ZHEJIANG University |
|
| TR01 | Transfer of patent right |